---
title: "BGB-43395 Plus Letrozole versus CDK4/6i Plus Letrozole for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease (BeOne/KANDELA-302)"
canonical: "https://www.renown.org/clinical-trials-directory/NCT07492641"
last_updated: "2026-10-09T22:05:06Z"
---

# BGB-43395 Plus Letrozole versus CDK4/6i Plus Letrozole for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease (BeOne/KANDELA-302)

URL: https://www.renown.org/clinical-trials-directory/NCT07492641

Short Title: BGB-43395

Enrollment Status: Recruiting

NCT #: [NCT07492641](https://clinicaltrials.gov/study/NCT07492641)

Specialty Area: Oncology

Condition Studied: Advanced or Metastatic HR+/HER2- Breast Cancer

Age Groups: Adult; Older Adult

Sex: All

Study Type: Interventional

Accepts Healthy Volunteers: No

Principal Investigator: Lee Schwartzberg, MD

Complete Study Details: https://clinicaltrials.gov/study/NCT07492641

## Study Information

### Summary / Purpose

To compare the effectiveness and safety of BGB-43395 in combination with letrozole or an investigator-selected approved CDK4/6 inhibitor for adults with advanced or metastatic HR-positive/HER2-negative breast cancer who have not previously received systemic anticancer treatment for advanced or metastatic disease.

### Who Can Participate

- Adults 18+ years of age
- Confirmed HR-positive/HER2-negative advanced or metastatic breast cancer
- No prior systemic anticancer treatment for advanced or metastatic disease
- Must have an ECOG performance status of 0–1 and either measurable disease by RECIST v1.1 or evaluable bone disease
- Visceral metastases may be eligible, but those with visceral crisis are excluded

### What's Involved

- Random assignment to receive either BGB-43395 plus letrozole or an investigator-selected CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) plus letrozole.
- Attending regular clinic visits
- Tumor imaging, laboratory testing, and safety assessments to monitor treatment response and side effects

## Additional Information

Location: Renown Health, Office of Clinical Research

Address: 1500 E 2nd St. Reno, NV 89502

General Research: [775-982-3646](tel:775-982-3646)

Oncology Research: [775-982-5050](tel:775-982-5050)

Email: [Renown-CRD@renown.org](mailto:Renown-CRD@renown.org)
